Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.
PharmaBoardroom is a site for senior professionals, providing global news, trends and reports relating to the pharmaceutical industry.
Today on 23rd March, we celebrate the Polish-Hungarian Friendship Day. We send our best wishes to our Hungarian colleagues and all lovers of Hungary. Poles and Hungarians have been bound by a close friendship for years. Let us wish that the historical slogan "Pole, Hungarian, two nephews" will never lose its validity. Minden jót!
EGIS has been present in Poland for 25 years and during this period we have always tried to be a partner for all health communities.